Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAA2 | P54646 | 1/20 | 0.47 |
| ▸ | GCGR | P47871 | 11/20 | 0.40 |
| ▸ | DHODH | Q02127 | 2/20 | 0.39 |
| ▸ | FABP4 | P15090 | 1/20 | 0.36 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.36 |
| ▸ | CETP | P11597 | 1/20 | 0.35 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
| ▸ | RXRA | P19793 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27525559 | 0.92 | PRKAA2 (0.51) | PRKAA2GCGRDHODHFABP4FABP5 | |
| SCHEMBL2646810 | 0.83 | PRKAA2 (0.47) | PRKAA2GCGR | |
| SCHEMBL9870568 | 0.82 | DPP4 (0.50) | PRKAA2GCGRDHODHFABP4FABP5 | |
| SCHEMBL2662929 | 0.79 | PRKAA2 (0.44) | PRKAA2GCGRCETPRXRA | |
| SCHEMBL2662912 | 0.76 | PRKAA2 (0.45) | PRKAA2GCGRCETP | |
| SCHEMBL9072602 | 0.74 | PRKAA2 (0.42) | PRKAA2GCGRDHODH | |
| SCHEMBL27295913 | 0.74 | DHODH (0.46) | PRKAA2GCGRDHODHFABP4FABP5 | |
| SCHEMBL27525560 | 0.74 | GCGR (0.43) | PRKAA2GCGRPTGDRPTGDR2 | |
| SCHEMBL27525530 | 0.73 | AR (0.42) | CETPPTGDR2 | |
| SCHEMBL2647009 | 0.73 | GAA (0.42) | GCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6218431-B1 | GLUCAGON RECEPTOR ANTAGONISTS FOR THERAPY OF DIABETES AND CONDITIONS ASSOCIATED WITH DIABETES | BAYER CORPORATION | 2001-04-17 | — | — | US | disclosed |
| EP-0934274-A1 | SUBSTITUTED PYRIDINES AND BIPHENYLS AS ANTI-HYPERCHOLESTERINEMIC, ANTI-HYPERLIPOPROTEINEMIC AND ANTI-HYPERGLYCEMIC AGENTS | Bayer Corporation (US) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998004528-A2 | SUBSTITUTED PYRIDINES AND BIPHENYLS AS ANTI-HYPERCHOLESTERINEMIC, ANTI-HYPERLIPOPROTEINEMIC AND ANTI-HYPERGLYCEMIC AGENTS | BAYER CORPORATION (US) | 1998-02-05 | — | — | WO | disclosed |